Portuguese | English

Pressione Enter para iniciar a Busca.

Volume 112, Nº 4, April 2019


DOI: http://www.dx.doi.org/10.5935/abc.20190029


PCSK9 Inhibitors: Clinical Relevance, Molecular Mechanisms, and Safety in Clinical Practice

Filipe Ferrari

Ricardo Stein

Marcelo Trotte Motta

Emilio Hideyuki Moriguchi

Dr. Filipe Ferrari

Figure 1 – Mechanisms of PCSK9 involvement in LDL metabolism.

Keywords: Cardiovascular Diseases/physiopathology; Coronary Artery Disease/mortality; Proprotein Convertase 9; Cholesterol, LDL; Lipoproteins; Anticholesteromic Agents.